IMA (ImageneBio) רווח נקי למניה (EPS TTM)

ImageneBio Inc is accelerating the release of anti-tumor agents through partnerships with oncology centers. Simultaneously, Ikena Oncology is researching neoplasm metabolism to develop precision therapies. High testing costs and patent protection create barriers to entry for new players, while the current metric stands at 61.40. This EPS (TTM) price visualization, which assists in the basic asset valuation, is provided below.

For an objective valuation of ImageneBio Inc (IMA), analyzing the growth rates of net income per share over the last twelve months is critical. The annual EPS TTM trend, which recorded a value of 61.40, reflects revenue volatility during the clinical scaling phase of oncology drugs, where sharp fluctuations in the indicator signal molecule verification costs and determine the investment attractiveness of the issuer's capital.